SANOFI DIABETES

Contacter le RP

Pour utiliser cette fonctionnalité, vous devez bénéficier d'un compte Babbler.

Content de vous revoir !

Télécharger ce contenu

Renseigner ces informations pour permettre à l’auteur de connaître ses lecteurs.

Adresse email invalide
Communiqué de presse

Toujeo® reduced risk of severe low blood sugar compared to insulin glargine
timer minutes de lecture minute de lecture

Copier le lien
toujeo-r-reduced-risk-of-severe-low-blood-sugar-compared-to-insulin-glargine

Cliquez sur l'image pour obtenir le format original

VIENNA - February 14, 2018 - With the continued evolution in diabetes care and a growing understanding of today’s insulin options, Sanofi is pleased to share new real-world evidence results which showed that Toujeo® (insulin glargine 300 Units/mL) significantly reduced the risk of severe low blood sugar (hypoglycemia) events compared to the long-acting insulins, insulin glargine 100 Units/mL (Lantus) and insulin detemir. These data are being presented at the 11th Annual Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Vienna, Austria.


Hit the download button to get the document.

  • Health & Medicine
  • Medicine
  • Men's Health
  • Women's Health

Autres actualités de la marque